4basebio (LON:4BB) Shares Up 1.2% - Still a Buy?

Key Points

• 4basebio PLC shares experienced a slight increase of 1.2%, trading at GBX 850 ($11.60), with a notable trading volume decline of 60% from the average.
• The company's market capitalization stands at £131.62 million, with a highly negative price-to-earnings ratio of -904.26 indicating potential financial challenges.
• 4basebio specializes in therapeutic synthetic DNA for gene therapies and vaccines, focusing on safe delivery methods for DNA/RNA based products.

4basebio PLC (LON:4BB - ) shares were up 1.2% during trading on Tuesday . The stock traded as high as GBX 850 ($11.60) and last traded at GBX 850 ($11.60). Approximately 472 shares traded hands during trading, a decline of 60% from the average daily volume of 1,181 shares. The stock had previously closed at GBX 840 ($11.47).

4basebio Trading Up 1.2%

The firm has a market capitalization of £131.62 million, a price-to-earnings ratio of -904.26 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The firm's 50-day simple moving average is GBX 925.18 and its 200 day simple moving average is GBX 1,038.88.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.